Morgans Senior Analyst Dr Derek Jellinek gives an update on ResMed's mixed 4Q, as strong sales across all product lines failed to translate into operating leverage. Check out more from Morgans: Visit the Morgans website: www.morgans.com.au Check out our blog: www.morgans.com.au/Blog On Facebook: www.facebook.com/MorgansAU On Instagram: www.instagram.com/Morgans.Australia On Twitter: twitter.com/MorgansAU
